ESPEROCT

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ESPEROCT
Generic name
ANTIHEMOPHILIC FACTOR (RECOMBINANT), GLYCOPEGYLATED-EXEI
Manufacturer
Novo Nordisk
Product type
PLASMA DERIVATIVE
SPL set ID
562f94e8-825f-4d7f-b93c-b783ac3a43bc
SPL ID
d47af230-b125-4bd9-b36c-51e8f90b22bc
Version
7
Effective date
2024-07-01
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:42

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, may occur. If a hypersensitivity reaction occurs, discontinue ESPEROCT and administer appropriate treatment. ( 5.1 ) • Development of neutralizing antibodies (inhibitors) has occurred. If bleeding is not controlled with the recommended dose of ESPEROCT, or if the expected plasma Factor VIII activity levels are not attained, then perform an assay that measures Factor VIII inhibitor concentration. ( 5.2 , 5.4 ) • Temporary decrease in Factor VIII incremental recovery has been observed after ESPEROCT infusion in previously untreated pediatric patients (PUPs). ( 5.3 ) 5.1 Hypersensitivity Reactions Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with ESPEROCT. The product contains traces of hamster proteins, which in some patients may cause allergic reactions [ see Description ( 11 )]. Early signs of allergic reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, difficulty breathing, wheezing, rash, hives, and itching. Observe patients for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of exposure to the product. Discontinue use of ESPEROCT if allergic- or anaphylactic-type reactions occur, and initiate appropriate treatment. 5.2 Neutralizing Antibodies The formation of neutralizing antibodies (inhibitors) to Factor VIII has occurred following administration of ESPEROCT. Monitor patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If expected Factor VIII activity plasma levels are not attained, or if bleeding is not controlled after ESPEROCT administration, suspect the presence of an inhibitor (neutralizing antibody) [ see Warnings and Precautions ( 5.3 ) ]. 5.3 Decreased Incremental Recovery in Previously Untreated Patients Incremental recovery (IR) is defined as the increase in plasma Factor VIII activity per IU/kg of ESPEROCT. Decreased IR, defined as having at least 2 consecutive observations of low IR values (<0.6 (IU/dL)/(IU/kg) after treatment with ESPEROCT, was observed in a trial of PUPs <6 years of age within the first 5 exposure days (ED) to ESPEROCT. Decreased IR was observed in 17 out of 59 (28.8%) subjects without factor VIII inhibition. This may be associated with high titers of anti-PEG binding antibodies. Decreased IR was temporary and returned to ≥ 0.6 (IU/dL)/(IU/kg) between 15 to 70 EDs if ESPEROCT was continued. As part of a post hoc subgroup analysis, the bleeding tendency was evaluated in the 17 subjects who experienced a temporary decreased IR. The mean treatment duration was 0.48 years, after which IR normalized in subjects continuing treatment (N=13). During the period of decreased IR, 14 out of 17 subjects experienced a total of 30 bleeds while on prophylaxis, of which 7 (23.3 %) were spontaneous. For non-inhibitor, non-decreased IR subjects, 36 (18.1%) of the total 199 bleeding episodes (mean treatment duration of 3.71 years) were reported as spontaneous. Subjects with decreased IR may have an increased bleeding tendency during the decreased IR period [ see Adverse Reactions (6.2) ]. If bleeding is not controlled with the recommended dose of ESPEROCT and/or the expected Factor VIII activity levels in the plasma are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency or discontinuing the product. 5.4 Monitoring Laboratory Tests If monitoring of Factor VIII is performed, use a chromogenic or one-stage clotting assay appropriate for use with ESPEROCT [ see Dosage and Administration ( 2 )]. Factor VIII activity levels can be affected by the type of activated partial thromboplastin time (aPTT) reagent used in the assay. Some silica-based aPTT reagents can underestimate the activity of ESPEROCT by up to 60%; other reagents may overestimate the activity by 20%. If an appropriate one-stage clotting or chromogenic assay is not available locally, then use a reference laboratory. If bleeding is not controlled with the recommended dose of ESPEROCT or if the expected Factor VIII activity levels in plasma are not attained, then perform a Bethesda assay to determine if Factor VIII inhibitors are present.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most frequently reported adverse reactions (incidence ≥1%) in previously treated patients (PTPs) and previously untreated patients (PUPs) in clinical trials were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (incidence ≥1%) in PUPs included Factor VIII inhibition (30%), and drug hypersensitivity (2.5%). The most frequently reported adverse reactions (≥ 1%) were rash, redness, itching and injection site reactions. ( 6 ) Additional frequently reported adverse reactions (≥ 1%) in PUPs included Factor VIII inhibition and hypersensitivity. (6) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of ESPEROCT has been evaluated in 270 subjects (202 adolescents/adults and 68 children) in five prospective, multi-center clinical studies in previously treated patients (PTPs) and 81 subjects (< 6 years of age) in one open-label, multi-center clinical study in previously untreated patients (PUPs) with severe hemophilia A (<1% endogenous Factor VIII activity) and no history of inhibitors. All subjects received at least one dose of ESPEROCT. A previously treated patient was defined as a subject with a history of at least 150 exposure days to other Factor VIII products (adolescent/adult subjects) or 50 exposure days to other Factor VIII products (pediatric subjects). A previously untreated patient was defined as a subject with a diagnosis of severe hemophilia A (FVIII activity level < 1%) based on medical records or central laboratory results with no prior use of purified Factor VIII containing clotting products (5 previous exposure days to blood components are acceptable). Total exposure of PTPs and PUPs to ESPEROCT was 80,425 exposure days corresponding to 889 patient years of treatment and 18,184 exposure days corresponding to 234 patient years of treatment, respectively. During the clinical trials in PTPs, adverse reactions occurred at a rate of 0.10 events per patient year of exposure. The most frequently reported adverse reactions were rash (5.2%), injection site reaction (2.6%), redness (1.9%), and itching (pruritus) (1.5%). During the clinical trial in PUPs, adverse reactions occurred at a rate of 0.25 events per patient year of exposure. The most frequently reported adverse reactions were Factor VIII inhibition (30%), injection site reaction (2.5%), drug hypersensitivity (2.5%), redness (1.2%), and rash (1.2%). 6.2 Immunogenicity In clinical trials with PTPs and PUPs, subjects were monitored for neutralizing antibodies to Factor VIII (Factor VIII inhibitor), and binding antibodies to Factor VIII or ESPEROCT, polyethylene glycol (PEG), or Chinese hamster ovary (CHO) host cell protein. Table 3 summarizes the number of subjects with anti-drug antibodies in PTPs and PUPs. Previously treated patients (PTPs) Of the 270 subjects in the PTP trials, 1 (0.4%) subject developed confirmed neutralizing antibodies to Factor VIII (13.5 Bethesda Units). In addition, 2 (0.7%) subjects had transient low titer FVIII antibody (<5 Bethesda Units) test results at a single occasion. Anti-PEG antibodies of no clinical consequence were detected in 43 (15.9%) PTPs, 32 (11.9%) of whom had pre-existing anti-PEG antibodies. Nine (3.3%) subjects developed anti-CHO host cell protein antibodies of no clinical consequence [ see Warnings and Precautions (5.2) ]. Previously untreated patients (PUPs) In a clinical trial in PUPs < 6 years of age, of the 80 treated subjects (excluding 1 subject with pre-existing Factor VIII inhibitors), 21 (26.3%) subjects developed Factor VIII inhibitors (≥ 0.6 Bethesda Units). Of 70 subjects with at least 10 exposure days to ESPEROCT or previously confirmed Factor VIII inhibitors, 21 (30%) subjects developed inhibitors, 11 (15.7%) of whom developed high titer inhibitors (≥ 5 Bethesda Units) and 10 (14.3%) of whom developed low titer inhibitors (< 5 Bethesda Units). Of total 21 subjects with inhibitors, two (2) subjects with high-titer FVIII inhibitor discontinued the trial. Six (6) of the remaining subjects (3 with high-titer and 3 with low-titer) were switched to immune tolerance induction therapy and completed the treatment. Two (2) subjects with high-titer inhibitor remained inhibitor positive until the end of the trial [ see Warnings and Precautions (5.2) ]. Of the 80 treated subjects, binding antibodies to Factor VIII or ESPEROCT, anti-PEG IgM, anti-PEG IgG, and anti-CHO host cell protein antibodies were developed in 42 (52.5%), 22 (27.5%), 50 (62.5%), and 7 (8.8%) subjects, respectively, except subjects who had pre-existing antibodies. Higher incidence of non-neutralizing antibodies binding to Factor VIII or ESPEROCT was observed in subjects with FVIII inhibitors (20/21, 95.2%) compared to subjects without inhibitors (22/59, 37.3%) whereas the development of anti-PEG IgM and IgG antibodies was not significantly different between inhibitor and non-inhibitor subjects. Table 3: Incidences of anti-drug antibodies in PTPs and PUPs PTP (all age) (N=270) n (%) PUP (< 6 years of age) (N=80) n (%) FVIII neutralizing antibodies Confirmed inhibitor (≥ 0.6 BU) 1 (0.4) 21 (26.3) High titer inhibitor (≥ 5 BU) 1 (0.4) 11 (13.8) Low titer inhibitor (< 5 BU) 0 10 (12.5) Anti-ESPEROCT/FVIII binding antibodies Conversion to positive antibodies 4 (1.5) 42 (52.5) Pre-existing antibodies 2 (0.7) 1 (1.3) Anti-PEG IgM antibodies Conversion to positive antibodies 11 (4.1) 22 (27.5) Pre-existing antibodies 32 (11.9) 16 (20) Anti-PEG IgG antibodies Conversion to positive antibodies NA 50 (62.5) Pre-existing antibodies NA 14 (17.5) Anti-CHO host cell protein antibodies Conversion to positive antibodies 9 (3.3) 7 (8.8) Pre-existing antibodies 2 (0.7) 2 (2.5) Note: “Conversion to positive antibodies” refers only to patients who were not detected with positive antibodies at baseline but developed antibodies post-baseline. “Pre-existing antibodies” refers to patients who were detected with positive antibodies at baseline. NA: Not analyzed In PUPs, high titers of anti-PEG IgG antibodies were associated with low Factor VIII incremental recovery (IR). In the PUP trial, a decreased Factor VIII IR, defined as at least 2 consecutive measurements of <0.6 (IU/dL)/(IU/kg) at 30 min post-dose, was identified after exposure to ESPEROCT (5 EDs) in 17 out of 59 (28.8%) subjects without detectable Factor VIII inhibitors, which was observed with increased titers of anti-PEG IgG antibodies. As treatment of ESPEROCT was continued, titers of anti-PEG IgG decreased and IR returned to ≥ 0.6 (IU/dL)/(IU/kg) between 15 to 70 EDs to ESPEROCT. A post hoc subgroup analysis indicated that subjects with decreased IR may have an increased bleeding tendency during the decreased IR period [ see Warnings and Precautions (5.3) ]. The detection of antibodies is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. 6.3 Postmarketing Experience The following adverse reactions have been identified during post-approval of ESPEROCT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decreased Factor VIII activity: There have been reports of decreased Factor VIII activity in the absence of detectable Factor VIII inhibitors in previously treated patients (PTPs) upon switching to ESPEROCT from other Factor VIII products.

adverse reactions table

<table width="100%"><col width="34%"/><col width="28%"/><col width="30%"/><thead><tr><th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"/><th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><content styleCode="bold">PTP (all age)</content> <content styleCode="bold">(N=270)</content> <content styleCode="bold">n (%)</content></th><th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><content styleCode="bold">PUP (&lt; 6 years of age) </content> <content styleCode="bold">(N=80)</content> <content styleCode="bold">n (%)</content></th></tr></thead><tbody><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">FVIII neutralizing antibodies</content></paragraph></td><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Confirmed inhibitor (&#x2265; 0.6 BU)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>1 (0.4)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>21 (26.3)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> High titer inhibitor (&#x2265; 5 BU)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>1 (0.4)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>11 (13.8)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Low titer inhibitor (&lt; 5 BU)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>0</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>10 (12.5)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Anti-ESPEROCT/FVIII binding antibodies </content></paragraph></td><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Conversion to positive antibodies</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>4 (1.5)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>42 (52.5)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Pre-existing antibodies</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>2 (0.7)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>1 (1.3)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Anti-PEG IgM antibodies</content></paragraph></td><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Conversion to positive antibodies</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>11 (4.1)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>22 (27.5)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Pre-existing antibodies</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>32 (11.9)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>16 (20)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Anti-PEG IgG antibodies</content></paragraph></td><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Conversion to positive antibodies</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>NA</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>50 (62.5)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Pre-existing antibodies</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>NA</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>14 (17.5)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Anti-CHO host cell protein antibodies</content></paragraph></td><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/><td styleCode="Rrule Lrule Toprule Botrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph> Conversion to positive antibodies</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>9 (3.3)</paragraph></td><td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>7 (8.8)</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph> Pre-existing antibodies</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph>2 (0.7)</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph>2 (2.5)</paragraph></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.